These data, reporting the beneficial effect of mTOR inhibition in the dorsal horn spinal cord or the dorsal root ganglia, together with our previous observations reporting the anti-allodynic effect of mTOR inhibition in CIPN and traumatic neuropathic pain models [21,22], prompted us to examine whether modulating 5-HT6 receptor activity and signaling in the spinal cord (i.e., where the pain signal is highly modulated by central top-down controls), could be effective in painful diabetic neuropathy. Here, MTOR is linked to diabetic neuropathy.